These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1761923)

  • 1. [Diabetes mellitus and its complications in Japan. Late complications of diabetes mellitus--estimation of risk factors in patients on sulfonylureas (Su) more than 10 years].
    Hoshi M; Fujita S
    Nihon Naika Gakkai Zasshi; 1991 Sep; 80(9):1432-3. PubMed ID: 1761923
    [No Abstract]   [Full Text] [Related]  

  • 2. Late complications of diabetes mellitus: risk factors in patients on sulfonylureas for more than 10 years.
    Hoshi M; Fujita S
    Jpn J Med; 1991; 30(6):616-7. PubMed ID: 1798228
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.
    Monami M; Genovese S; Mannucci E
    Diabetes Obes Metab; 2013 Oct; 15(10):938-53. PubMed ID: 23594109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular safety of sulphonylurea: comment on the study by Monami et al.
    Du L; Chen Y; Shen J; Peng Y; Sun X
    Diabetes Obes Metab; 2014 Jul; 16(7):667-9. PubMed ID: 24320700
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse.
    Corley BT; Davenport C; Delaney L; Hatunic M; Smith D
    Diabet Med; 2011 Jul; 28(7):876-9. PubMed ID: 21204965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
    Sillars B; Davis WA; Hirsch IB; Davis TM
    Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.
    Garratt KN; Brady PA; Hassinger NL; Grill DE; Terzic A; Holmes DR
    J Am Coll Cardiol; 1999 Jan; 33(1):119-24. PubMed ID: 9935017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
    Barry HC
    Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 10. [Controversial aspects regarding metformin in type 2 diabetic patient: reduction of late complications in early, single drug administration; increased risk of death in later administration in combination with sulfonylurea compounds].
    Ritzmann P
    Praxis (Bern 1994); 1999 Aug; 88(33):1330-1. PubMed ID: 10483287
    [No Abstract]   [Full Text] [Related]  

  • 11. [Differential therapy using oral antidiabetics].
    Mehnert H
    Internist (Berl); 1971 Nov; 12(11):468-75. PubMed ID: 4943878
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical trial of glypizide].
    Cañadell Vidal J
    Rev Iber Endocrinol; 1974 Jan; 21(121):61-73. PubMed ID: 4826383
    [No Abstract]   [Full Text] [Related]  

  • 13. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
    Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry.
    Danchin N; Charpentier G; Ledru F; Vaur L; Guéret P; Hanania G; Blanchard D; Lablanche JM; Genès N; Cambou JP
    Diabetes Metab Res Rev; 2005; 21(2):143-9. PubMed ID: 15386810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas].
    Gonçalves JV; Caldeira J
    Rev Port Cardiol; 2001 Apr; 20(4):439-45. PubMed ID: 11433889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality.
    Shimoda M; Kaku K
    J Diabetes Investig; 2016 Sep; 7(5):674-6. PubMed ID: 27181105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril.
    Rett K; Wicklmayr M; Dietze GJ
    N Engl J Med; 1988 Dec; 319(24):1609. PubMed ID: 3059189
    [No Abstract]   [Full Text] [Related]  

  • 20. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis.
    Phung OJ; Schwartzman E; Allen RW; Engel SS; Rajpathak SN
    Diabet Med; 2013 Oct; 30(10):1160-71. PubMed ID: 23663156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.